<p>阿尔凯默斯公司 (NASDAQ:ALKS - 免费报告) - HC Wainwright 在 5 月 18 日周一向投资者发布的报告中下调了对阿尔凯默斯 2026 财年的每股收益 (EPS) 预期。HC Wainwright 分析师 D. Tsao 现在预测该公司将发布每股收益为（$0.44），低于之前预测的（$0.41）。HC Wainwright 对该股票的评级为 “中性”，目标价为$43.00。市场普遍预计阿尔凯默斯当前全年的每股收益为（$0.42）。</p>
<p>其他一些券商也对 ALKS 发表了看法。美国银行在 4 月 9 日的研究报告中将阿尔凯默斯的目标价从$34.00 上调至$36.00，并给予该公司 “中性” 评级。加拿大皇家银行在 2 月 26 日的研究报告中将阿尔凯默斯的目标价从$47.00 下调至$45.00，并对该公司给予 “跑赢大盘” 评级。瑞银集团在 5 月 6 日的研究报告中将阿尔凯默斯的目标价从$42.00 上调至$48.00，并给予该公司 “买入” 评级。富国银行在 5 月 6 日的研究报告中将阿尔凯默斯的目标价从$43.00 上调至$44.00，并给予该公司 “增持” 评级。最后，Wolfe Research 在 2 月 23 日的研究报告中开始覆盖阿尔凯默斯，给予 “跑赢大盘” 评级和$45.00 的目标价。一位分析师对该股票给予强烈买入评级，十一位分析师给予买入评级，五位分析师给予持有评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为$45.40。</p>
<p><strong>获取我们关于阿尔凯默斯的最新报告</strong></p>
<h2>阿尔凯默斯股价下跌 0.5%</h2>
<p>阿尔凯默斯股票在周三以$37.00 开盘。该公司的市值为$61.7 亿，市盈率为 41.11，贝塔值为 0.31。该公司的 50 日移动平均价格为$32.83，200 日移动平均价格为$31.41。公司流动比率为 1.70，当前比率为 2.27，债务与股本比率为 0.85。阿尔凯默斯的 12 个月低点为$25.17，12 个月高点为$39.56。</p>
<p>阿尔凯默斯 (NASDAQ:ALKS - 获取免费报告) 最近在 2 月 14 日发布了季度财报。该公司报告季度每股收益为$0.29。该季度的营业收入为$3.8455 亿。阿尔凯默斯的股本回报率为 9.26%，净利润率为 9.78%。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近增加或减少了对该股票的持股。Sanctuary Advisors LLC 在第四季度将其在阿尔凯默斯的持股增加了 2.7%。Sanctuary Advisors LLC 目前拥有该公司 12,141 股股票，价值$340,000，在上个季度又增持了 315 股。PNC 金融服务集团在第四季度将其在阿尔凯默斯的持股增加了 3.5%。PNC 金融服务集团目前拥有该公司 10,326 股股票，价值$289,000，在上个季度又增持了 351 股。Orion Portfolio Solutions LLC 在第三季度将其在阿尔凯默斯的持股增加了 4.5%。Orion Portfolio Solutions LLC 目前拥有该公司 8,762 股股票，价值$263,000，在上个季度又增持了 376 股。Horizon Investments LLC 在第三季度将其在阿尔凯默斯的持股增加了 0.9%。Horizon Investments LLC 目前拥有该公司 43,002 股股票，价值$1,290,000，在上个季度又增持了 387 股。最后，AMG National Trust Bank 在第三季度将其在阿尔凯默斯的持股增加了 0.6%。AMG National Trust Bank 目前拥有该公司 60,175 股股票，价值$1,805,000，在上个季度又增持了 388 股。对冲基金和其他机构投资者持有该公司 95.21% 的股份。</p>
<h2>内部买卖</h2>
<p>在相关消息中，执行副总裁 Craig C. Hopkinson 于 5 月 1 日星期五出售了 9,000 股阿尔凯默斯股票。该股票以平均价格$33.40 出售，总价值为$300,600.00。交易完成后，该执行副总裁持有该公司 81,389 股股票，价值约为$2,718,392.60。这笔交易代表其持股减少了 9.96%。该交易已在 SEC 的法律文件中披露，可以通过此超链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，高级副总裁 Christian Todd Nichols 于 3 月 2 日星期一出售了 6,000 股阿尔凯默斯股票。该股票以平均价格$30.00 出售，总价值为$180,000.00。交易完成后，该高级副总裁持有该公司 109,769 股股票，价值约为$3,293,070。这代表其持股减少了 5.18%。该销售的披露信息可在 SEC 文件中找到。在上个季度，内部人士出售了 39,102 股公司股票，价值$1,265,090。公司内部人士持有该公司 4.59% 的股份。</p>
<h2>关于阿尔凯默斯</h2>
<p>(获取免费报告)</p>
<p>阿尔凯默斯公司是一家生物制药公司，专注于开发创新药物，以满足中枢神经系统 (CNS) 的未满足需求。该公司运用其专有的药物递送技术和治疗专业知识，推进对成瘾、精神分裂症、双相 I 型障碍和抑郁症的治疗。阿尔凯默斯的产品组合包括多个商业产品和一系列旨在改善患者结果和支持长期疾病管理的研究性疗法。</p>
<p>阿尔凯默斯的商业产品线包括多个已获批准的产品。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票而非阿尔凯默斯</li>
<li>HIVE 利用权力进行 AI 转型</li>
<li>深入分析 NVIDIA 最新的投资组合动态</li>
<li>Brady Corp 进行大规模 AI 驱动的突破</li>
<li>为什么家得宝的抛售可能成为一个巨大的机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw"/></p>
<p><em>这条即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何关于此故事的问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在阿尔凯默斯吗？</h2>
<p>在你考虑阿尔凯默斯之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿尔凯默斯并不在名单上。</p>
<p>虽然阿尔凯默斯目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿尔凯默斯

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>HC Wainwright 将 Alkermes plc 的 2026 财年每股收益预测从（$0.41）下调至（$0.44）。该公司维持 “中性” 评级，目标价为 $43.00。其他分析师的意见各不相同，摩根大通将其目标价上调至 $36.00，瑞银集团则将其上调至 $48.00。Alkermes 的股票开盘价为 $37.00，市值为 61.7 亿美元</p>

<p>Alkermes plc (NASDAQ:ALKS - Free Report) - HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Alkermes in a note issued to investors on Monday, May 18th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.44) for the year, down from their prior forecast of ($0.41). HC Wainwright has a &#34;Neutral&#34; rating and a $43.00 price objective on the stock. The consensus estimate for Alkermes' current full-year earnings is ($0.42) per share.</p>
<div class="lb-trans"><p>阿尔凯默斯公司 (NASDAQ:ALKS - 免费报告) - HC Wainwright 在 5 月 18 日周一向投资者发布的报告中下调了对阿尔凯默斯 2026 财年的每股收益 (EPS) 预期。HC Wainwright 分析师 D. Tsao 现在预测该公司将发布每股收益为（$0.44），低于之前预测的（$0.41）。HC Wainwright 对该股票的评级为 “中性”，目标价为$43.00。市场普遍预计阿尔凯默斯当前全年的每股收益为（$0.42）。</p>
</div><p>A number of other brokerages have also weighed in on ALKS. Bank of America raised their price objective on Alkermes from $34.00 to $36.00 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, April 9th. Royal Bank Of Canada cut their price objective on Alkermes from $47.00 to $45.00 and set an &#34;outperform&#34; rating for the company in a research report on Thursday, February 26th. UBS Group raised their price objective on Alkermes from $42.00 to $48.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, May 6th. Wells Fargo &amp; Company raised their price objective on Alkermes from $43.00 to $44.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, May 6th. Finally, Wolfe Research began coverage on Alkermes in a research report on Monday, February 23rd. They set an &#34;outperform&#34; rating and a $45.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $45.40.</p>
<div class="lb-trans"><p>其他一些券商也对 ALKS 发表了看法。美国银行在 4 月 9 日的研究报告中将阿尔凯默斯的目标价从$34.00 上调至$36.00，并给予该公司 “中性” 评级。加拿大皇家银行在 2 月 26 日的研究报告中将阿尔凯默斯的目标价从$47.00 下调至$45.00，并对该公司给予 “跑赢大盘” 评级。瑞银集团在 5 月 6 日的研究报告中将阿尔凯默斯的目标价从$42.00 上调至$48.00，并给予该公司 “买入” 评级。富国银行在 5 月 6 日的研究报告中将阿尔凯默斯的目标价从$43.00 上调至$44.00，并给予该公司 “增持” 评级。最后，Wolfe Research 在 2 月 23 日的研究报告中开始覆盖阿尔凯默斯，给予 “跑赢大盘” 评级和$45.00 的目标价。一位分析师对该股票给予强烈买入评级，十一位分析师给予买入评级，五位分析师给予持有评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为$45.40。</p>
</div><p><strong>Get Our Latest Report on Alkermes</strong></p>
<div class="lb-trans"><p><strong>获取我们关于阿尔凯默斯的最新报告</strong></p>
</div><h2>Alkermes Trading Down 0.5%</h2>
<div class="lb-trans"><h2>阿尔凯默斯股价下跌 0.5%</h2>
</div><p>Shares of Alkermes stock opened at $37.00 on Wednesday. The firm has a market cap of $6.17 billion, a price-to-earnings ratio of 41.11 and a beta of 0.31. The business has a 50-day moving average price of $32.83 and a 200-day moving average price of $31.41. The company has a quick ratio of 1.70, a current ratio of 2.27 and a debt-to-equity ratio of 0.85. Alkermes has a twelve month low of $25.17 and a twelve month high of $39.56.</p>
<div class="lb-trans"><p>阿尔凯默斯股票在周三以$37.00 开盘。该公司的市值为$61.7 亿，市盈率为 41.11，贝塔值为 0.31。该公司的 50 日移动平均价格为$32.83，200 日移动平均价格为$31.41。公司流动比率为 1.70，当前比率为 2.27，债务与股本比率为 0.85。阿尔凯默斯的 12 个月低点为$25.17，12 个月高点为$39.56。</p>
</div><p>Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The company reported $0.29 EPS for the quarter. The business had revenue of $384.55 million for the quarter. Alkermes had a return on equity of 9.26% and a net margin of 9.78%.</p>
<div class="lb-trans"><p>阿尔凯默斯 (NASDAQ:ALKS - 获取免费报告) 最近在 2 月 14 日发布了季度财报。该公司报告季度每股收益为$0.29。该季度的营业收入为$3.8455 亿。阿尔凯默斯的股本回报率为 9.26%，净利润率为 9.78%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC grew its position in Alkermes by 2.7% in the fourth quarter. Sanctuary Advisors LLC now owns 12,141 shares of the company's stock worth $340,000 after acquiring an additional 315 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Alkermes by 3.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,326 shares of the company's stock worth $289,000 after acquiring an additional 351 shares in the last quarter. Orion Porfolio Solutions LLC grew its position in Alkermes by 4.5% in the third quarter. Orion Porfolio Solutions LLC now owns 8,762 shares of the company's stock worth $263,000 after acquiring an additional 376 shares in the last quarter. Horizon Investments LLC grew its position in Alkermes by 0.9% in the third quarter. Horizon Investments LLC now owns 43,002 shares of the company's stock worth $1,290,000 after acquiring an additional 387 shares in the last quarter. Finally, AMG National Trust Bank grew its position in Alkermes by 0.6% in the third quarter. AMG National Trust Bank now owns 60,175 shares of the company's stock worth $1,805,000 after acquiring an additional 388 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对该股票的持股。Sanctuary Advisors LLC 在第四季度将其在阿尔凯默斯的持股增加了 2.7%。Sanctuary Advisors LLC 目前拥有该公司 12,141 股股票，价值$340,000，在上个季度又增持了 315 股。PNC 金融服务集团在第四季度将其在阿尔凯默斯的持股增加了 3.5%。PNC 金融服务集团目前拥有该公司 10,326 股股票，价值$289,000，在上个季度又增持了 351 股。Orion Portfolio Solutions LLC 在第三季度将其在阿尔凯默斯的持股增加了 4.5%。Orion Portfolio Solutions LLC 目前拥有该公司 8,762 股股票，价值$263,000，在上个季度又增持了 376 股。Horizon Investments LLC 在第三季度将其在阿尔凯默斯的持股增加了 0.9%。Horizon Investments LLC 目前拥有该公司 43,002 股股票，价值$1,290,000，在上个季度又增持了 387 股。最后，AMG National Trust Bank 在第三季度将其在阿尔凯默斯的持股增加了 0.6%。AMG National Trust Bank 目前拥有该公司 60,175 股股票，价值$1,805,000，在上个季度又增持了 388 股。对冲基金和其他机构投资者持有该公司 95.21% 的股份。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $33.40, for a total value of $300,600.00. Following the completion of the transaction, the executive vice president owned 81,389 shares in the company, valued at approximately $2,718,392.60. This trade represents a 9.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christian Todd Nichols sold 6,000 shares of Alkermes stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $30.00, for a total value of $180,000.00. Following the completion of the transaction, the senior vice president owned 109,769 shares of the company's stock, valued at approximately $3,293,070. This represents a 5.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 39,102 shares of company stock worth $1,265,090. Corporate insiders own 4.59% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Craig C. Hopkinson 于 5 月 1 日星期五出售了 9,000 股阿尔凯默斯股票。该股票以平均价格$33.40 出售，总价值为$300,600.00。交易完成后，该执行副总裁持有该公司 81,389 股股票，价值约为$2,718,392.60。这笔交易代表其持股减少了 9.96%。该交易已在 SEC 的法律文件中披露，可以通过此超链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，高级副总裁 Christian Todd Nichols 于 3 月 2 日星期一出售了 6,000 股阿尔凯默斯股票。该股票以平均价格$30.00 出售，总价值为$180,000.00。交易完成后，该高级副总裁持有该公司 109,769 股股票，价值约为$3,293,070。这代表其持股减少了 5.18%。该销售的披露信息可在 SEC 文件中找到。在上个季度，内部人士出售了 39,102 股公司股票，价值$1,265,090。公司内部人士持有该公司 4.59% 的股份。</p>
</div><h2>About Alkermes</h2>
<div class="lb-trans"><h2>关于阿尔凯默斯</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.</p>
<div class="lb-trans"><p>阿尔凯默斯公司是一家生物制药公司，专注于开发创新药物，以满足中枢神经系统 (CNS) 的未满足需求。该公司运用其专有的药物递送技术和治疗专业知识，推进对成瘾、精神分裂症、双相 I 型障碍和抑郁症的治疗。阿尔凯默斯的产品组合包括多个商业产品和一系列旨在改善患者结果和支持长期疾病管理的研究性疗法。</p>
</div><p>Alkermes' commercial franchise features several approved products.</p>
<div class="lb-trans"><p>阿尔凯默斯的商业产品线包括多个已获批准的产品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Alkermes</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非阿尔凯默斯</li>
<li>HIVE 利用权力进行 AI 转型</li>
<li>深入分析 NVIDIA 最新的投资组合动态</li>
<li>Brady Corp 进行大规模 AI 驱动的突破</li>
<li>为什么家得宝的抛售可能成为一个巨大的机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ALKS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这条即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何关于此故事的问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Alkermes Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在阿尔凯默斯吗？</h2>
</div><p>Before you consider Alkermes, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑阿尔凯默斯之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿尔凯默斯并不在名单上。</p>
</div><p>While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿尔凯默斯目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 下调了阿尔凯默斯 2026 财年的每股收益预测